Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer

Journal of the National Cancer Institute

Volumn 97, Issue 9, 2005, Pages 632-642

  Palmiere, Diane ^a   Halverson, Douglas O ^a   Ouatas, Taoufik ^a,d   Horak, Christine E ^a   Salerno, Massimiliano ^a   Johnson, Jennifer ^b   Figg, W Douglas ^a   Hollingshead, Melinda ^a   Hursting, Stephen ^a   Berrigan, David ^a   Steinberg, Seth M ^a   Merino, Maria J ^a   Steeg, Patricia S ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Endotis Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR; MEDROXYPROGESTERONE ACETATE; NUCLEOSIDE DIPHOSPHATE KINASE A; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; COMPLEMENTARY DNA; NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; BLOOD; BREAST TUMOR; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA, ANTISENSE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MEDROXYPROGESTERONE 17-ACETATE; MICE; NUCLEOSIDE-DIPHOSPHATE KINASE; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 20444447134     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji111     Document Type: Article

References (70)

1. Steeg P. Metastasis suppressors alter the signal transduction of cancer cells. Nat Cancer Rev 2003;3:55-63.
2. Yoshida B, Sokoloff M, Welch D, Rinker-Schaeffer C. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000;92:1717-30.
3. Shevde L, Welch D. Metastasis suppressor pathways - an evolving paradigm. Cancer Lett 2003; 198:1-20.
4. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
5. Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991;65:25-35.
6. Lacombe ML, Milon L, Munier A, Mehus J, Lambeth D. The human Nm23/ nucleoside diphosphate kinases. J Bioenerg Biomembr 2000;32:247-58.
7. Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization, and enzymatic activity. Oncogene 1993;8:2325-33.
8. Bhujwalla Z, Aboagye E, Gilles R, Chack V, Mendola C, Backer J. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magnetic Res Med 1999;41:897-903.
9. Russell R, Geisinger K, Mehta R, White W, Shelton B, Kute T. nm23 - Relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts and lymph node negative breast carcinoma patients. Cancer 1997;79:1158-65.
10. Fukuda M, Ishii A, Yasutomo Y, Shimada N, Ishikawa N, Hanai N, et al. Metastatic potential of rat mammary adenocarcinoma cells associated with decreased expression of nucleoside diphosphate kinase/nm23: reduction by transfection of NDP Kinase a isoform, an nm23-H2 gene homolog. Int J Cancer 1996;65:531-7.
11. Baba H, Urano T, Okada K, Furukawa K, Nakayama E, Tanaka H, et al. Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res 1995;55:1977-81.
12. Miele ME, Rosa AD, Lee JH, Hicks DJ, Dennis JU, Steeg PS, et al. Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (nm23). Clin Exp Metastasis 1997;15:259-65.
13. Parhar RS, Shi Y, Zou M, Farid NR, Ernst P, Al-Sedairy S. Effects of cytokine mediated modulation of Nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Int J Cancer 1995;60:204-10.
14. Tagashira H, Hamazaki K, Tanaka N, Gao C, Namba M. Reduced metastatic potential and c-myc overexpression of colon adenocarcinoma cells (Colon 26 line) transfected with nm23-R2 rat nucleoside diphosphate kinase a isoform. Int J Mol Med 1998;2:65-8.
15. Miyazaki H, Fukuda M, Ishijima Y, Negishi A, Hirayama R, Ishikawa N, et al. Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture. Clin Cancer Res 1999;5:4301-7.
16. Suzuki E, Ota T, Tsukuda K, Okita A, Matsuoka K, Murakami M, et al. nm23-H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation. Int J Cancer 2004;108:207-11.
17. Kantor JD, McCormick B, Steeg PS, Zetter BR. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res 1993;53:1971-3.
18. Howlett AR, Petersen OW, Steeg PS, Bissell MJ. A novel function for Nm23: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 1994;86: 1838-44.
19. Russell R, Pedersen A, Kantor J, Geisinger K, Long R, Zbieranski N, et al. Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer 1998;78:710-7.
20. Bemis L, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res 2000;60:3414-8.
21. Smukste I, Stockwell B. Restoring functions of tumor suppressors with small molecules. Cancer Cell 2003;4:419-20.
22. Cropp C, Lidereau R, Leone A, Liscia D, Cappa A, Campbell G, et al. NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. J Natl Cancer Inst 1994;86:1167-9.
23. Hartsough M, Clare S, Mair M, Elkahloun A, Sgroi D, Osborne C, et al. Elevation of breast carcinoma nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 2001;61:2320-7.
24. Lin K, Wang W, Wu Y, Cheng S. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its a-receptor. Endocrinology 2002;143:467-75.
25. Liu F, Qi HL, Chen HL. Effects of all-trans retinoic acid and epidermal growth factor on the expression of nm23-H1 in human hepatocarcinoma cells. J Cancer Res Clin Oncol 2000;126:85-90.
26. Jiang W, Hiscox S, Bryce R, Horrobin D, Mansel R. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. Br J Cancer 1988;77:731-8.
27. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, et al. The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 2002;32:838-46.
28. Ouatas T, Clare S, Hartsough M, DeLaRosa A, Steeg P. MMTV-associated transcription factor binding sites increase nm23-H1 metastasis suppressor gene expression in human breast carcinoma cell lines. Clin Exp Metastasis 2002;19:35-42.
29. Ouatas T, Halverson D, Steeg P. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 2003;9:3763-72.
30. Skegg D, Noonan E, Paul C, Spears G, Meirik O, Thomas D. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995;273: 799-804.
31. Stockler M, Wilcken N, Ghersi D, Simes R. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-68.
32. Focan C, Beauduin M, Salamon E, Greve JD, deWasch G, Lobelle J, et al. Adjuvant high dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. Br J Cancer 2001;85:1-8.
33. Hori T, Kodama H, Nishimura S, Hatano T, Okamura R, Fujii K, et al. A randomized study comparing oral and standard regimens for metastatic breast cancer. Oncol Rep 2001;8:1067-71.
34. Bryne M, Gebski V, Forbes J, Tattersall M, Simes R, Coates A, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: A Phase III randomized trial. J Clin Oncol 1997;15:3141-8.
35. Bentel J, Birrell S, Pickering M, Holds D, Horsfall D, Tilley W. Androgen receptor agonist activity of the synthetic progestin medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 1999; 154:11-20.
36. Selman P, Wolfswinkel J, Mol J. Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. Steroids 1996;61:133-7.
37. Bamberger C, Else T, Bamberger A, Beil F, Shulte H. Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Biol Chem 1999;84:4055-61.
38. Lan L, Vinci J, Melendez J, Jeffrey J, Wilcox B. Progesterone mediates decreases in uterine smooth muscle cell interelukin-1a by a mechanism involving decreased stability of IL-1a mRNA. Mol Cell Endocrinol 1999;155:123-33.
39. Shiozawa T, Horiuchi A, Kato K, Obinata M, Konishi I, Fuji S, et al. Up-regulation of p27Kip1 by progestins is involved in the growth suppression of the normal and malignant human endometrial glandular cells. Endocrinology 2001;142:4182-8.
40. Hupperets P, Wils J, Volovics L, Schouten L, Fickers M, Bron H, et al. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluroruacil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up. The Breast 2001;10:35-7.
41. Nagy T, Clair A. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 2000;8:392-8.
42. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
43. Packard G, Boardman T. The misuse of ratios, indices, and percentages in ecophysiological research. Physiol Zool 1988;61:1-9.
44. Nishimura R, Nagao K, Matsuda M, Baba K, Matsuoka Y, Yamashita H, et al. Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer. Eur J Cancer 1997;33:1407-12.
45. Etienne M, Milano G, Frenay M, Renee N, Francois E, Thyss A, et al. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advance breast cancer patients. J Clin Oncol 1992;10:1176-82.
46. Davila E, Vogel C, East D, Cairns V, Hilsenbeck S. Clinical trial of high dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer 1988;61:2161-7.
47. Gallagher CJ, Cairnduff F, Smith IE. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 1987;23:1895-900.
48. Koyama H, Tominaga T, Asaishi K, Abe R, Iino Y, Enomoto K, et al. A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer. Oncology 1999;56:283-90.
49. Ishida Y, Heersche J. Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos Int 2002;13:601-5.
50. Pazos P, Lanari C, Elizalde P, Montecchia F, Charreau E, Molinolo A. Promoter effect of medroxyprogesterone acetate (MPA) in N-methyl-N-nitrosourea (MNU) induced mammary tumors in BALB/c mice. Carcinogenesis 1998;19:529-31.
51. Lanari C, Molonolo A, Pasqualini C. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c mice. Cancer Lett 1986;33:215-33.
52. Chekmareva M, Kadkhodaian M, Hollowell C, Kim H, Yoshida B, Luu H, et al. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micro-metastases. Cancer Res 1998;58:4963-9.
53. Goldberg S, Harms J, Quon K, Welch D. Metastasis suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis 1999;58:4963-9.
54. Leo J, Guo C, Woon C, Aw S, Lin V. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesions and growth inhibition in breast cancer cells. Endocrinology 2004;145:1314-21.
55. Lin V, Jin R, Tan PH, Aw SE, Woon CT, Bay BH. Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am J Pathol 2003;162: 1781-7.
56. Swarbrick A, Lee C, Sutherland R, Musgrove E. Cooperation of p27Kip1 and p18Ink4c in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol 2000;20:2581-91.
57. Alkhalaf M, El-Mowafy A. Overexpression of wild-type p53 gene renders MCF-7 breast cancer cells more sensitive to the antiproliferative effect of progesterone. J Endocrinol 2003;179:55-62.
58. Ahola T, Manninen T, Alkio N, Ylikomi T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002;143:3376-84.
59. Sugimoto T, Shiba E, Watanabe T, Takai S. Suppression of parathyroid hormone-related protein messenger RNA expression by medroxyprogesterone acetate in breast cancer tissues. Breast Cancer Res Treat 1999;56: 11-23.
60. Thuneke I, Shulte H, Bamberger A. Biphasic effect of medroxyprogesterone acetate (MPA) treatment on proliferation and cyclin D1 gene transcription in T47D breast cancer cells. Breast Cancer Res Treat 2000; 63:243-8.
61. Mizukami Y, Tajiri K, Nonomura A, Nogichi M, Taniya T, Koyasaki N, et al. Effects of tamoxifen, medroxyprogesterone acetate and estradiol on tumor growth and oncogene expression in MCF-7 breast cancer cell line transplanted into nude mice. Anticancer Res 1991;11:1333-8.
62. Yamaji T, Tsuboi H, Murata N, Uchida M, Kohno T, Sugino E, et al. Anti-angiogenic activity of a novel synthetic agent, 9-a-flurormedroxyprogesterone acetate. Cancer Lett 1999;145:107-14.
63. Yuyama Y, Yagihashi A, Hirata K, Suzuki Y, Ohmura T, Okazaki M, et al. The effects of epirubicin hydrochloride (EPI) plus pretreatment of medroxyprogesterone acetate (MPA) on FM3A breast cancer cells transplanted in female C3H/He mice. In Vivo 2003;17:251-4.
64. vanVeelen H, Willemse P, Sleijfer D, Sluiter W, Doorenbos H. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. Cancer Treat Rep 1985;9:977-83.
65. Sunil N, Bennett J, Haslam S. Hepatocyte growth factor is required for progestin-induced epithelial cell proliferation and alveolar-like morphogenesis in serum-free culture of normal mammary epithelial cells. Endocrinology 2002;143:2953-60.
66. Ballare C, Uhrig M, Bechtold T, Sancho E, DiDomenico M, Migliaccio A, et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003;23:1994-2008.
67. Seeger H, Wallwiener D, Mueck A. The effect of progesterone and synthetic progestins on serum-and estradiol-stimulated proliferation of human breast cancer cells. Horm Metab Res 2003;35:76-80.
68. Wan Y, Nordeen S. Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol 2002;16:1204-14.
69. Deroo B, Archer T. Differential activation of the IkBa and mouse mammary tumor virus promoters by progesterone and glucocorticoid receptors. J Steroid Biochem Mol Biol 2002;81:309-17.
70. Song LN, Huse B, Rusconi Simons SS Jr. Transactivation specificity of glucocorticoid versus progesterone receptors. J Biol Chem 2001; 276:24806-16.